Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIR-3434, BRII-877
Tobevibart · 5 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Participants will receive treatment with tobevibart + elebsiran up to 240 weeks. |
| Arm 2 | EXPERIMENTAL | Participants will receive Bulevirtide for 24 weeks and switch to receive tobevibart + elebsiran for additional 216 weeks |
| Arm 1 (Tobevibart + Elebsiran) | EXPERIMENTAL | Participants will receive treatment with tobevibart + elebsiran for 240 weeks. |
| Arm 2 (Tobevibart + Elebsiran) | EXPERIMENTAL | Participants will receive tobevibart + elebsiran after an observational period for 240 weeks. |
| STRIVE: Cohort 1a (VIR-3434 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total |
| STRIVE: Cohort 2a (VIR-3434 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total |
| STRIVE: Cohort 3a (VIR-3434 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total |
| STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total |
| STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total |
| THRIVE: Cohort 1b (VIR-3434 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks |
| THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | EXPERIMENTAL | Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total |
| VIR-3434 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tobevibart | DRUG | Tobevibart administered by subcutaneous injection |
| Elebsiran | DRUG | Elebsiran administered by subcutaneous injection |
| Bulevirtide | DRUG | Bulevirtide administered by subcutaneous injection |
| VIR-3434 | DRUG | VIR-3434 given by subcutaneous injection |
| VIR-2218 | DRUG | VIR-2218 given by subcutaneous injection |
| TDF | DRUG | TDF given orally |
| PEG-IFNα | DRUG | PEG-IFNα given by subcutaneous injection |
| Placebo | OTHER | Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion. |
Inclusion Criteria: 1. Male or female ages 18 to 70 years at screening 2. HDV RNA ≥ 500 IU/mL at screening 3. Receiving BLV 2 mg SC QD for ≥ 24 weeks at Day 1 4. Noncirrhotic or compensated cirrhotic liver disease at screening 5. On NRTI therapy against HBV for at least 12 weeks prior to day 1 or h...
Tobevibart is an investigational biologic developed by Vir Biotechnology, Inc. (ticker VIR) for chronic hepatitis B and viral hepatitis. It is being studied in clinical trials, including a Phase 1/2 platform study in chronic hepatitis B infection and later-phase studies in chronic hepatitis D infection given in combination with elebsiran.
Tobevibart targets hepatitis B surface antigen, or HBsAg. By binding HBsAg, the investigational antibody is designed to act on the surface antigen of the hepatitis B virus. Vir Biotechnology is developing it as a biologic for chronic hepatitis B and viral hepatitis, and it is also being studied in combination with elebsiran.
Tobevibart is developed by Vir Biotechnology, Inc., which trades under the ticker VIR. The company is studying the investigational biologic in chronic hepatitis B and viral hepatitis, including combination studies with elebsiran in chronic hepatitis D infection across multiple countries.
Tobevibart is in Phase 1/2 development overall and is investigational; it is not approved. Its chronic hepatitis B program includes a completed Phase 1/Phase 2 platform study, while combination studies with elebsiran in chronic hepatitis D infection are listed at Phase 2 and Phase 3. The FDA has granted Tobevibart Fast Track designation.
Tobevibart has been studied in the Phase 1/Phase 2 platform trial NCT05612581 in chronic hepatitis B infection, which is completed. Active studies of Tobevibart plus elebsiran in chronic hepatitis D infection include NCT07142811 (Phase 2), NCT07128550 (Phase 3), and NCT06903338 (Phase 3), all currently active and not recruiting.
Yes, VIR-3434 is another name for Tobevibart. Vir Biotechnology (ticker VIR) uses both names for the same investigational biologic targeting HBsAg, which is being studied in chronic hepatitis B and viral hepatitis, including combination trials with elebsiran in chronic hepatitis D infection.